NEW
YORK, Feb. 13, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical
company, today announced that Robb
Knie, Chief Executive Officer, is scheduled to attend the
BIO CEO and Investor Conference in New
York, NY.
To learn more about BIO CEO and Investor Conference please visit
https://bcic.bio.org/.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.
is a clinical-stage biopharmaceutical company focused on developing
new generation therapies for dermatological disorders. Hoth's
pipeline has the potential to improve the quality of life for
patients suffering from indications including atopic dermatitis,
chronic wounds, psoriasis, asthma, and acne. Hoth has also recently
entered into two different agreements to further the development of
two different vaccine prospects to prevent or treat COVID-19. To
learn more, please visit https://ir.hoththerapeutics.com/.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-to-attend-bio-ceo-and-investor-conference-february-26-27-2024-302060867.html
SOURCE Hoth Therapeutics, Inc.